Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fortive
FTV
|
+$1.27B |
| 2 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$706M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$439M |
| 4 |
Invesco QQQ Trust
QQQ
|
+$413M |
| 5 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$272M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Weyerhaeuser
WY
|
+$431M |
| 2 |
Walt Disney
DIS
|
+$223M |
| 3 |
VXX
iPath S&P 500 VIX Short-Term Futures ETN due 1/30/2019
VXX
|
+$213M |
| 4 |
Halliburton
HAL
|
+$211M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$204M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 8.34% |
| 2 | Financials | 5.75% |
| 3 | Healthcare | 5.71% |
| 4 | Consumer Discretionary | 5.08% |
| 5 | Industrials | 3.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4126
CALL
Becton Dickinson
BDX
$49.5B
| $548K | ﹤0.01% |
2,153
-10,352
| -83% | -$2.55M |
|
4127
PUT
Plains All American Pipeline
PAA
$16.6B
| $548K | ﹤0.01% |
21,900
-32,500
| -60% | -$818K |
|
4128
CALL
Pan American Silver
PAAS
$20.5B
| $548K | ﹤0.01% |
37,100
+12,900
| +53% | +$206K |
|
4129
Fate Therapeutics
FATE
$298M
| $547K | ﹤0.01% |
33,527
+26,085
| +351% | +$308K |
|
4130
CALL
SBA Communications
SBAC
$19.8B
| $546K | ﹤0.01% |
3,400
-4,100
| -55% | -$654K |
|
|
BHR
4131
Braemar Hotels & Resorts
BHR
$138M
| $545K | ﹤0.01% |
46,742
+14,968
| +47% | +$168K |
|
|
EVRI
4132
DELISTED
Everi Holdings
EVRI
| $544K | ﹤0.01% |
59,311
+46,530
| +364% | +$382K |
|
|
SEI
4133
Solaris Energy Infrastructure
SEI
$3.94B
| $543K | ﹤0.01% |
28,764
-15,539
| -35% | -$249K |
|
4134
Accuray
ARAY
$32.9M
| $542K | ﹤0.01% |
120,506
-160,953
| -57% | -$634K |
|
|
RCM
4135
DELISTED
R1 RCM Inc. Common Stock
RCM
| $542K | ﹤0.01% |
53,265
+10,338
| +24% | +$94.2K |
|
4136
CRISPR Therapeutics
CRSP
$5.13B
| $541K | ﹤0.01% |
12,181
-4,590
| -27% | -$240K |
|
4137
PUT
FMC
FMC
$1.26B
| $541K | ﹤0.01% |
7,149
-3,689
| -34% | -$278K |
|
|
CTLP
4138
DELISTED
Cantaloupe
CTLP
| $540K | ﹤0.01% |
74,913
+69,813
| +1,369% | +$962K |
|
|
MODN
4139
DELISTED
MODEL N, INC.
MODN
| $540K | ﹤0.01% |
34,063
+32,216
| +1,744% | +$564K |
|
4140
PUT
Apollo Global Management
APO
$84.5B
| $539K | ﹤0.01% |
15,600
-89,000
| -85% | -$3.1M |
|
4141
Iovance Biotherapeutics
IOVA
$2.92B
| $539K | ﹤0.01% |
47,860
+34,846
| +268% | +$495K |
|
4142
CALL
Zillow
ZG
$7.86B
| $539K | ﹤0.01% |
12,200
-13,600
| -53% | -$711K |
|
|
LORL
4143
DELISTED
Loral Space and Communications, Inc.
LORL
| $539K | ﹤0.01% |
11,862
+4,033
| +52% | +$166K |
|
4144
PUT
Magna International
MGA
$18.6B
| $536K | ﹤0.01% |
10,200
+7,600
| +292% | +$427K |
|
4145
UNIFI
UFI
$120M
| $536K | ﹤0.01% |
18,949
+12,737
| +205% | +$398K |
|
|
4146
PUT
Weyerhaeuser
WY
$17.9B
| $536K | ﹤0.01% |
16,600
+4,700
| +39% | +$163K |
|
|
REV
4147
DELISTED
Revlon, Inc.
REV
| $536K | ﹤0.01% |
24,002
+11,680
| +95% | +$221K |
|
|
DCH
4148
CALL
Dauch Corp
DCH
$1.6B
| $535K | ﹤0.01% |
30,700
+3,300
| +12% | +$56.7K |
|
4149
Wave Life Sciences
WVE
$1.03B
| $534K | ﹤0.01% |
10,687
-2,103
| -16% | -$94.9K |
|
|
FPRX
4150
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $534K | ﹤0.01% |
38,354
+33,584
| +704% | +$499K |
|
Similar funds
Barclays's Q3 2018 Portfolio in Review
As of Q3 2018, Barclays held 7,740 positions worth $144B, up 24% from $116B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Barclays deployed $22.2B of net new capital in Q3 2018, opening 680 new positions and adding to 3,884 existing holdings. Its largest new stake was iPath Series B S&P GSCI Crude Oil ETN: 5,000,000 shares worth $75.7M.
By sector, the portfolio is most concentrated in Technology at 8.3% of assets, up from 7.5% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Weyerhaeuser, an estimated $431M trimmed.
- Barclays's largest Q3 2018 buy was iPath Series B S&P GSCI Crude Oil ETN: 5,000,000 shares worth $75.7M.
- Barclays added most to Fortive in Q3 2018, an estimated $1.27B increase.
- Barclays's biggest Q3 2018 reduction was Weyerhaeuser, cutting an estimated $431M.
- Barclays fully exited Validus Hold Ltd in Q3 2018, selling an estimated $71M.
- Barclays's ten largest holdings make up 31% of its $144B portfolio in Q3 2018.
- Barclays opened 680 new positions and closed 408 in Q3 2018.
- Barclays's portfolio value rose 24% quarter-over-quarter to $144B.
Based on Barclays's 13F filing for Q3 2018, filed 14 Nov 2018.